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Identity 
Other names: IPCA-1, IPCA1, PCANAP1, PUMPCn, 
STAMP1, STMP 




Human STEAP2 gene was identified by using 
subtraction and cDNA arrays hybridizations in  
benign prostate hyperplasia and PC-3 prostate cancer 
cell line (Porkka et al., 2002). This gene is a memb r of 
the STEAP family and encodes a multi-pass membrane 
protein. 
Transcription 
The main STEAP2 transcript (variant 1) contains 5 
exons and encodes a protein with 490 amino acids. The 
variant 2 differs from variant 1 in the 5' UTR, but 
encodes the same protein. The variant 3 differs in the 5' 
UTR, 3' UTR and 3' coding region compared to variant 
1, resulting in a protein (isoform B) with unique C-
terminus.  
 
Figure 1. Genomic organization of STEAP2 and its transcripts. 
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Figure 2. Amino acids sequence of STEAP2 isoform A and B (Korkmaz et al., 2002). 
 
The lengths of these transcripts are:  
- Variant 1: 6932 kb transcript; 1470 bp ORF, 
- Variant 2: 6708 kb transcript; 1470 bp ORF, 
- Variant 3: 2320 kb transcript; 1362 bp ORF. 
Protein 
Note 
Members of this family are characterized by a six 
transmembrane helical domains. 
Description 
The main isoform (STEAP2 isoform A) is encoded by 
variant 1 and variant 2 mRNA. This isoform contains 
490 amino acids (NCBI: NP_694544.2), 60 kDa and 
contains six transmembrane helical domains (figure 2).  
The variant 3 mRNA encodes a protein (STEAP2 
isoform B) that is shorter and has a unique C-terminus, 
compared to isoform A. However, none study has 
identified this isoform in in vitro or in vivo, yet. This 
putative isoform contains 454 amino acids (NCBI: 
NP_001035756.1), a 52 kDa and six transmembrane 
helical domains (figure 2). 
Expression 
STEAP2 is expressed exclusively in the epithelial cells 
of the prostate. In relation to prostate cell lines,  
STEAP2 is highly expressed in androgen receptor-
positive cancer cell line LNCaP, CWR22 and CWR22R 
(Korkmaz et al., 2002).  
Regarding to human tissues, STEAP2 is mainly 
expressed in prostate, but also in heart, brain, kidney, 
pancreas, ovary, fetal liver, colon, duodenum, ileum, 
liver, lung, stomach, thymus, choroid plexus and 
mesenchymal stem cells (Korkmaz et al., 2002; 
Ohgami et al., 2006; Vaghjiani et al., 2009). 
Localisation 
STEAP2 is localized mainly at plasma membrane, but 
also in trans-Golgi network and vesicular tubular 
structures (Korkmaz et al., 2002). 
Function 
Recently, it was demonstrated that STEAP2 acts as 
ferrireductase and cupric reductase, stimulating cellular 
uptake of both iron and copper (Ohgami et al., 2006). 
Moreover, its localization also suggests an important 
role in secretory/endocytic pathways (Korkmaz et al., 
2002). 
Furthermore, it was demonstrated that STEAP2 
contains a domain associated to apoptosis and cancer, 
suggesting its involvement in cell cycle regulation 
(Sanchez-Pulido et al., 2004). 
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Homology 
STEAP2 is known to have orthologs in chimpanzees, 
dogs, cows, mice, rats, chickens and even fish (NCBI: 
Homologene). Additional putative orthologs are likely 




A great variety of single nucleotide polymorphisms 
(SNPs) have been identified, but its clinical 
significance remains unknown (NCBI: SNPs). 






STEAP2 is highly expressed in androgen receptor-
positive prostate cancer cell line LNCaP, but not i the 
androgen receptor-negative prostate cancer cell lines 
PC-3 and DU-145. However, STEAP2 expression is 
not significantly regulated by androgens in prostate 
cancer cells (Korkmaz et al., 2002). In human prostate 
tissues, STEAP2 is expressed exclusively in the 
epithelial cells of the prostate and its expression is 
significantly increased in prostate tumours compared 
with normal glands (Korkmaz et al., 2002). Moreover, 
STEAP2 expression is higher in both untreated primary 
and hormone-refractory prostate carcinomas than in 
benign prostate hyperplasias, suggesting an important 
role in prostate cancer progression. As a cell-surface 
antigen, STEAP2 is a potential diagnostic or 
therapeutic target in prostate cancer (Porkka et al., 
2002). 
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